N
ANAB icon

Natixis’s AnaptysBio ANAB Stock Holding History

Natixis’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5K Buy
+333
New +$17.9K ﹤0.01% 1009
2025
Q2 		– Sell
-2,669
Closed -$48.8K – 1030
2025
Q1 		$48.8K Buy
+2,669
New +$44.5K ﹤0.01% 834
2022
Q2 		– Sell
-16,300
Closed -$403K – 1149
2022
Q1 		$403K Sell
16,300
-142,700
-90% -$4.32M ﹤0.01% 1017
2021
Q4 		$5.53M Buy
+159,000
New +$5.04M 0.02% 535

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Natixis's ANAB Position: Q1 2026 in Review

Natixis opened a new position in AnaptysBio (ANAB) in Q1 2026: 333 shares worth $18.5K. The stake represents ﹤0.01% of the portfolio and ranks #1009 among its holdings. This is a return to the name: Natixis previously reported a position in ANAB as recently as Q1 2025.

Natixis first reported a position in ANAB in Q4 2021 and has held it in 4 quarters since. The position peaked at $5.53M in Q4 2021. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Natixis held 333 shares of AnaptysBio worth $18.5K as of Q1 2026.
  • AnaptysBio was a new Natixis position in Q1 2026.
  • AnaptysBio made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1009 holding.
  • Natixis first reported a position in AnaptysBio in Q4 2021 and has held it in 4 quarters since.
  • Natixis's AnaptysBio position peaked at $5.53M in Q4 2021.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.